<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Drug design, drug delivery and technologies</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Researchers identify innate immune barrier against melanoma</title>
      <description>
        <![CDATA[Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live melanoma cells, and the discovery could reshape thinking around macrophage-targeted cancer therapies and innate immunity in oncology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731270</guid>
      <pubDate>Tue, 26 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731270-researchers-identify-innate-immune-barrier-against-melanoma</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/Phan-Lab-Garvan-Institute-Melanoma-imaging-05-26-26.webp?t=1779807535" type="image/jpeg" medium="image" fileSize="901145">
        <media:title type="plain">Microscopy of a cross-section of mouse skin containing melanoma tumors</media:title>
        <media:description type="plain">Microscopy of a cross-section of mouse skin containing melanoma tumors. CD169+ macrophages are shown in green and yellow, forming a distinct boundary as they attempt to locally contain the cancer. Credit: Phan Lab, Garvan Institute</media:description>
      </media:content>
    </item>
    <item>
      <title>‘Detargeted’ targeted gene therapy improves activity in Pompe</title>
      <description>
        <![CDATA[A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme and the vector that delivers it to the target tissue while avoiding the liver. The findings suggest that combining an optimized transgene with a targeted capsid could significantly enhance the effectiveness of gene therapy for Pompe disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731174</guid>
      <pubDate>Wed, 20 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731174-detargeted-targeted-gene-therapy-improves-activity-in-pompe</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Acid-alpha-glucosidase-molecular-structure.webp?t=1779288468" type="image/jpeg" medium="image" fileSize="390572">
        <media:title type="plain">Acid alpha-glucosidase molecular structure isolated on black</media:title>
      </media:content>
    </item>
    <item>
      <title>Launch of CGTxchange to reactivate cell and gene therapy programs</title>
      <description>
        <![CDATA[The American Society of Gene & Cell Therapy (ASGCT) and Orphan Therapeutics Accelerator (OTXL) have announced the public launch of CGTxchange, an AI-enhanced clearinghouse and marketplace built to help reactivate cell and gene therapy programs that have been shelved despite strong scientific and clinical evidence.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731124</guid>
      <pubDate>Fri, 15 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731124-launch-of-cgtxchange-to-reactivate-cell-and-gene-therapy-programs</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Archive-room.webp?t=1778858165" type="image/jpeg" medium="image" fileSize="314054">
        <media:title type="plain">Dimly lit archive room filled with cardboard storage boxes</media:title>
      </media:content>
    </item>
    <item>
      <title>ASGCT 2026: Directed evolution in gene therapy</title>
      <description>
        <![CDATA[Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and delivery vectors. Molecular diversification methods are increasingly sophisticated and are now accelerated by machine learning and AI tools, as showcased at the 29th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) held in Boston this week.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731119</guid>
      <pubDate>Fri, 15 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731119-asgct-2026-directed-evolution-in-gene-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/DNA-and-genome-editing.webp?t=1778858165" type="image/jpeg" medium="image" fileSize="96216">
        <media:title type="plain">DNA and genome editing illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>ASGCT 2026: Uncovering the mechanisms of AAV toxicity</title>
      <description>
        <![CDATA[Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other delivery strategies. Each combination is optimized for a specific cell type and indication, aiming to overcome challenges such as efficacy, specificity and toxicity. On May 13, 2026, two sessions included in the scientific symposia of the 29th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), being held in Boston this week, addressed AAV-related toxicities, which have led to fatal cases in clinical trials and remain an area for improvement in approved therapies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731091</guid>
      <pubDate>Thu, 14 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731091-asgct-2026-uncovering-the-mechanisms-of-aav-toxicity</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Colorful-adeno-associated-viruses-AAVs.webp?t=1778776816" type="image/png" medium="image" fileSize="1832336">
        <media:title type="plain">3D illustration of adeno-associated viruses</media:title>
      </media:content>
    </item>
    <item>
      <title>ASGCT 2026: Circular RNA, the new beast in gene and cell therapy</title>
      <description>
        <![CDATA[Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine, this RNA fragment without free ends surpasses their performance in both efficacy and durability, bringing it to the attention of several pioneering companies. The latest advances in circRNA presented at the 29th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) clearly surpass the performance achieved with linear mRNA.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731268</guid>
      <pubDate>Wed, 13 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731268-asgct-2026-circular-rna-the-new-beast-in-gene-and-cell-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/glowing-circle-illustration.webp?t=1778686093" type="image/png" medium="image" fileSize="673869">
        <media:title type="plain">Illustration of a glowing circle to represent circRNA</media:title>
      </media:content>
    </item>
    <item>
      <title>Two-step HIV vaccine induces broadly neutralizing antibodies</title>
      <description>
        <![CDATA[A designed chimeric virus induced broadly neutralizing antibodies against the macaque equivalent of HIV. The strategy works in two steps: first it uses an envelope protein with a mutation that reduces the glycan shield that makes it invisible to the immune system, and then it exposes the part of the protein most likely to generate these antibodies capable of blocking many variants of the virus. The macaques developed potent and diverse antibodies with this approach, which pave the way for the development of an HIV-1 vaccine.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731222</guid>
      <pubDate>Tue, 12 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731222-two-step-hiv-vaccine-induces-broadly-neutralizing-antibodies</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Infection-3D-illustration-HIV-enveloped.webp?t=1778251655" type="image/png" medium="image" fileSize="1917557">
        <media:title type="plain">3D illustration of enveloped HIV </media:title>
      </media:content>
    </item>
    <item>
      <title>New assay for drug discovery against chemo-induced peripheral neuropathy</title>
      <description>
        <![CDATA[A group led by researchers at Boston Children’s Hospital established a scalable and reproducible model of paclitaxel-induced axon degeneration and neurotoxicity in human induced pluripotent stem cell (iPSC)-derived sensory neurons.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730951</guid>
      <pubDate>Fri, 08 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730951-new-assay-for-drug-discovery-against-chemo-induced-peripheral-neuropathy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Neurology-neuron-pathways.webp?t=1685635688" type="image/jpeg" medium="image" fileSize="225697">
        <media:title type="plain">Concept art for "unlocking the secrets of the mind"</media:title>
      </media:content>
    </item>
    <item>
      <title>Two-step HIV vaccine induces broadly neutralizing antibodies</title>
      <description>
        <![CDATA[A designed chimeric virus induced broadly neutralizing antibodies (bNAbs) against the macaque equivalent of HIV. The strategy works in two steps: first it uses an envelope protein (Env) with a mutation that reduces the glycan shield that makes it invisible to the immune system, and then it exposes the part of the protein most likely to generate these antibodies capable of blocking many variants of the virus. The macaques developed potent and diverse antibodies with this approach, which pave the way for the development of an HIV-1 vaccine.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730947</guid>
      <pubDate>Fri, 08 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730947-two-step-hiv-vaccine-induces-broadly-neutralizing-antibodies</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Infection-3D-illustration-HIV-enveloped.webp?t=1778251655" type="image/png" medium="image" fileSize="1917557">
        <media:title type="plain">3D illustration of enveloped HIV </media:title>
      </media:content>
    </item>
    <item>
      <title>First measles treatment advances as vaccination rates drop</title>
      <description>
        <![CDATA[Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry into the cell. This is the first time that antibodies have been shown to bind effectively to two essential viral proteins, creating a dual blockade that prevents infection. Unlike the current vaccine, which is based on an attenuated virus and is not recommended for immunocompromised individuals, these monoclonal antibodies could be used both as a new vaccine approach and as a treatment for the entire population.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730929</guid>
      <pubDate>Thu, 07 May 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730929-first-measles-treatment-advances-as-vaccination-rates-drop</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/F_Fab1.webp?t=1778167596" type="image/png" medium="image" fileSize="120510">
        <media:title type="plain">Rendering of a key measles protein targeted by neutralizing human antibodies</media:title>
        <media:description type="plain">This rendering shows a key measles protein (white) targeted by neutralizing human antibodies (pink). Credit: Dawid Zyla, La Jolla Institute for Immunology</media:description>
      </media:content>
    </item>
    <item>
      <title>MYO technology enables DNA delivery of incretin agonists for durable weight loss</title>
      <description>
        <![CDATA[Researchers from Renbio Inc. and Louisiana State University investigated the delivery of plasmid DNA encoding new glucagon-like peptide-1(GLP-1)-based biologics with MYO (Make Your Own) technology as a new therapeutic strategy. This approach ensures the continuous production of GLP-1-based biologics for an extended period, overcoming the need for weekly dosing.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730903</guid>
      <pubDate>Wed, 06 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730903-myo-technology-enables-dna-delivery-of-incretin-agonists-for-durable-weight-loss</link>
    </item>
    <item>
      <title>Liposomes displaying Env trimers drive HIV apex-focused responses</title>
      <description>
        <![CDATA[A new vaccination strategy designed to induce antibodies that recognize the apex of the HIV Env protein uses Env trimers displayed on liposomes to increase their density and orient them correctly. This presentation enhanced apex-focused antibody responses in macaques, and the monoclonal antibodies isolated after immunization showed binding modes and structural features resembling human broadly neutralizing antibodies (bNAbs), indicating that the vaccine can steer the antibody response toward this vulnerable site.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730811</guid>
      <pubDate>Mon, 04 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730811-liposomes-displaying-env-trimers-drive-hiv-apex-focused-responses</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Infections-HIV-envelope-trimer.webp?t=1777906764" type="image/jpeg" medium="image" fileSize="1070153">
        <media:title type="plain">Illustration of HIV showing trimers</media:title>
      </media:content>
    </item>
    <item>
      <title>Quintuple GLP-1-GIP-PPAR agonist for obesity and diabetes control</title>
      <description>
        <![CDATA[A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome proliferator activated receptors (PPAR α/γ/δ). GLP-1-GIP-Lani enables targeted delivery of the PPAR agonist to cells that express incretin receptors, enhancing weight loss, improving glucose control and reducing inflammation in obese mice. In these models, it surpassed the effects of GLP-1 receptor agonists such as semaglutide and GLP-1-GIP co-agonists such as tirzepatide in reducing body weight, improving glycemic control and enhancing metabolic outcomes during active treatment.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730790</guid>
      <pubDate>Thu, 30 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730790-quintuple-glp-1gipppar-agonist-for-obesity-and-diabetes-control</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Glucagon-like-peptide-1-receptor-GLP-1R-binding-site-small-molecule-agonist.webp?t=1777564710" type="image/jpeg" medium="image" fileSize="637678">
        <media:title type="plain">Glucagon-like peptide-1 receptor (GLP-1R) complex</media:title>
        <media:description type="plain">Glucagon-like peptide-1 receptor (GLP-1R) complex, representing the molecular target for GLP-1 agonists. Detailed view of the binding site with small-molecule agonist.</media:description>
      </media:content>
    </item>
    <item>
      <title>Financing supports Fathom Therapeutics’ Microcosmos drug design engine</title>
      <description>
        <![CDATA[Fathom Therapeutics, formerly Atommap Corp., has raised $47 million in an oversubscribed series A financing to advance its work using physics-based simulations and AI to model protein motion and interactions at atomic resolution.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730719</guid>
      <pubDate>Tue, 28 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730719-financing-supports-fathom-therapeutics-microcosmos-drug-design-engine</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/finance-dollar-growth.webp?t=1638226495" type="image/png" medium="image" fileSize="416016">
        <media:title type="plain">Hand holding dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Novel method BOOSTs organ growth after transplantation</title>
      <description>
        <![CDATA[A major challenge in tissue engineering is not only achieving the correct cellular organization of an engineered tissue, but also expanding it to a clinically useful size after implantation. Researchers from the Wyss Institute at Harvard University have developed a synthetic biology platform that genetically programs tissues to grow large organ implants on demand. Building on a 2017 study suggesting engineered liver tissues could respond to regenerative signals released after injury, the researchers set out to identify and harness those cues.
<br><br>
  “If we could figure out what those signals were, we could synthetically drive these factors locally in an implant to control its growth ourselves,” first author Amy Stoddard told <em>BioWorld</em>. Stoddard is a postdoctoral researcher at the Wyss Institute.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730717</guid>
      <pubDate>Tue, 28 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730717-novel-method-boosts-organ-growth-after-transplantation</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Neon-arrows.webp?t=1777389173" type="image/jpeg" medium="image" fileSize="548927">
        <media:title type="plain">Pink and blue neon arrows demonstrating acceleration</media:title>
      </media:content>
    </item>
    <item>
      <title>Pharma industry faces long haul to get return on investment from AI</title>
      <description>
        <![CDATA[Artificial intelligence tools are springing up at multiple points along drug discovery and development, but despite the hype, as yet there is minimal return on investment (ROI). “I would say a lot of companies sort of get this big excitement about AI, but then when you look at how much ROI they get, it’s actually very little. And that’s because the workflow and the process, end-to-end, isn’t mapped to really understand where AI can truly make an impact,” said Laura Matz, chief science and technology officer at Merck KGaA.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730716</guid>
      <pubDate>Fri, 24 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730716-pharma-industry-faces-long-haul-to-get-return-on-investment-from-ai</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/AI/AI-drug-development-illustration.webp?t=1776978683" type="image/jpeg" medium="image" fileSize="1049020">
        <media:title type="plain">Glowing neural network inside a transparent capsule surrounded by a large language model</media:title>
      </media:content>
    </item>
    <item>
      <title>Detecting the invisible: minimal residual disease at AACR 2026</title>
      <description>
        <![CDATA[Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision. As increasingly sensitive technologies reveal traces of cancer that persist after therapy, MRD is emerging as both a biological challenge and a clinical opportunity, especially as new data illuminate its complexity across hematologic and solid tumors. This topic was addressed at the 2026 American Association for Cancer Research (AACR) annual meeting. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730633</guid>
      <pubDate>Fri, 24 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730633-detecting-the-invisible-minimal-residual-disease-at-aacr-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Cancer-tumor-tissue-growth.webp?t=1777041759" type="image/jpeg" medium="image" fileSize="653690">
        <media:title type="plain">Illustration of a tumor</media:title>
      </media:content>
    </item>
    <item>
      <title>AACR 2026: The age of agentic AI in oncology</title>
      <description>
        <![CDATA[New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of experimental compounds fail in clinical trials, underscoring the need for strategies that better capture human biology. Many of these techniques were showcased at the 2026 American Association for Cancer Research (AACR) annual meeting.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730582</guid>
      <pubDate>Thu, 23 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730582-aacr-2026-the-age-of-agentic-ai-in-oncology</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/AI/Abstract-digital-human-face-AI.webp?t=1776955679" type="image/jpeg" medium="image" fileSize="303061">
        <media:title type="plain">Illustration of human face that looks abstract and digital</media:title>
      </media:content>
    </item>
    <item>
      <title>Serif Biomedicines launches with modified DNA platform</title>
      <description>
        <![CDATA[Flagship Pioneering Inc. has announced the launch of Serif Biomedicines Inc., a biotechnology company pioneering modified DNA as a new class of medicines. Modified DNA brings together the best features of mRNA and gene therapy, while mitigating their limitations, by enabling medicines that are programmable, scalable, durable and redosable.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730555</guid>
      <pubDate>Wed, 22 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730555-serif-biomedicines-launches-with-modified-dna-platform</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Digital-DNA-double-helix-light-particles.webp?t=1776870451" type="image/jpeg" medium="image" fileSize="550567">
        <media:title type="plain">DNA double helix illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Kaleidoscope-like ‘engineered disorder’ expands imaging potential</title>
      <description>
        <![CDATA[A new metasurface design strategy that replaces rigid order with “engineered disorder” could significantly increase how many optical functions can be integrated into a single ultra-thin device without increasing size or complexity, according to a study published in <em>Nature Communications</em>. The study challenges a longstanding assumption in optical engineering that highly ordered, periodic structures are required to precisely control light.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730575</guid>
      <pubDate>Tue, 21 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730575-kaleidoscope-like-engineered-disorder-expands-imaging-potential</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Misc/kaleidoscope-pattern-art.webp?t=1776355120" type="image/jpeg" medium="image" fileSize="1285474">
        <media:title type="plain">Photo of kaleidoscope pattern</media:title>
      </media:content>
    </item>
    <item>
      <title>At AACR: Epigenetic fingerprints in metastases track tumor origin</title>
      <description>
        <![CDATA[When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on machine learning has identified DNA-methylation patterns that reveal the type of tissue a cancer comes from when the primary tumor cannot be found. This technique could help guide more specific treatments for patients with cancers of unknown primary, who today often receive broad, nontargeted chemotherapy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730535</guid>
      <pubDate>Tue, 21 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730535-at-aacr-epigenetic-fingerprints-in-metastases-track-tumor-origin</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Cancer-tumor-metastasis.webp?t=1776781708" type="image/jpeg" medium="image" fileSize="740126">
        <media:title type="plain">Illustration of metastatic cancer</media:title>
      </media:content>
    </item>
    <item>
      <title>Kaleidoscope-like ‘engineered disorder’ expands imaging potential</title>
      <description>
        <![CDATA[A new metasurface design strategy that replaces rigid order with “engineered disorder” could significantly increase how many optical functions can be integrated into a single ultra-thin device without increasing size or complexity, according to a study published in <em>Nature Communications</em>. The study challenges a longstanding assumption in optical engineering that highly ordered, periodic structures are required to precisely control light.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730425</guid>
      <pubDate>Thu, 16 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730425-kaleidoscope-like-engineered-disorder-expands-imaging-potential</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Misc/kaleidoscope-pattern-art.webp?t=1776355120" type="image/jpeg" medium="image" fileSize="1285474">
        <media:title type="plain">Photo of kaleidoscope pattern</media:title>
      </media:content>
    </item>
    <item>
      <title>New guidance advises on assessing safety of gene editing </title>
      <description>
        <![CDATA[The U.S. FDA’s latest draft guidance on gene therapies focuses on nonclinical studies using next-generation sequencing-based methods and bioinformatics to evaluate safety risks associated with off-target editing and loss of genome integrity in human gene-edited products.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730446</guid>
      <pubDate>Wed, 15 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730446-new-guidance-advises-on-assessing-safety-of-gene-editing</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Gene-editing-CRISPR.webp?t=1599848770" type="image/png" medium="image" fileSize="484156">
        <media:title type="plain">Gene editing illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>More of everything as Amazon moves into AI-driven drug R&amp;D</title>
      <description>
        <![CDATA[Amazon is extending the reach of its “everything store” into drug R&D with the launch of an artificial intelligence-powered Bio Discovery business. The company has compiled a catalogue of 40-plus foundation models that have been trained on extensive biology datasets and are able to generate and evaluate drug molecules in silico. For now, this covers antibodies only, but it is intended to move into other modalities.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730445</guid>
      <pubDate>Wed, 15 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730445-more-of-everything-as-amazon-moves-into-ai-driven-drug-r-and-d</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Amazon-Bio-Discovery-4-14.webp?t=1776201314" type="image/jpeg" medium="image" fileSize="234848">
        <media:title type="plain">Amazon Bio Discovery AI-powered application</media:title>
        <media:description type="plain">The Amazon Bio Discovery AI agent helps scientists set up and run AI-powered drug discovery workflows. Credit: www.aboutamazon.com</media:description>
      </media:content>
    </item>
    <item>
      <title>Financing at Vivatides to advance extrahepatic RNA therapeutics</title>
      <description>
        <![CDATA[Vivatides Therapeutics Inc. has closed an oversubscribed $54 million series A financing to advance its work in extrahepatic RNA delivery technologies. Proceeds from the financing will be used to further advance the company’s extrahepatic delivery platform and accelerate pipeline programs.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730327</guid>
      <pubDate>Mon, 13 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730327-financing-at-vivatides-to-advance-extrahepatic-rna-therapeutics</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Dollar-sign-between-hands.webp?t=1740610521" type="image/jpeg" medium="image" fileSize="123345">
        <media:title type="plain">Dollar sign between hands</media:title>
      </media:content>
    </item>
    <item>
      <title>Biologics in development outnumber small molecules for the first time</title>
      <description>
        <![CDATA[More than four decades on from the approval of the first biologic drug, the industry has reached a tipping point, and biotech drugs now outnumber small molecules in the global R&D pipeline. At the start of the biotech industry, progress was slow. Between 1983 and 1995, the U.S. FDA approved an average of two biologics each year. Now, biologics have taken the lead by the smallest of margins, accounting for 50.1% of drugs in development at the start of 2026, according to the <em>Pharma Annual Review 2026</em>, published by Pharmaprojects, a firm that tracks global pharma R&D.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730343</guid>
      <pubDate>Fri, 10 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730343-biologics-in-development-outnumber-small-molecules-for-the-first-time</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Drug-research-illustration1.webp?t=1600982220" type="image/png" medium="image" fileSize="443224">
        <media:title type="plain">Drug research illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Smart contact lens delivers adaptative glaucoma therapy</title>
      <description>
        <![CDATA[A smart polymer contact lens measures intraocular pressure (IOP) in real time and automatically releases medication into the eye when IOP goes beyond a critical limit. This technological advance, developed by scientists at the Terasaki Institute for Biomedical Innovation (TIBI), could enable personalized glaucoma therapy, avoiding poor patient adherence to their prescribed regimen and eliminating the need for bulky electronic devices. Animal models tolerate it well and, although the load is concentrated at the edges of the lens, it is still unknown how it could affect visual acuity.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730276</guid>
      <pubDate>Thu, 09 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730276-smart-contact-lens-delivers-adaptative-glaucoma-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-anatomy-and-contact-lens.webp?t=1775678594" type="image/jpeg" medium="image" fileSize="480794">
        <media:title type="plain">Eye anatomy and contact lens</media:title>
      </media:content>
    </item>
    <item>
      <title>Smart contact lens delivers adaptative glaucoma therapy</title>
      <description>
        <![CDATA[A smart polymer contact lens measures intraocular pressure (IOP) in real time and automatically releases medication into the eye when IOP goes beyond a critical limit. This technological advance, developed by scientists at the Terasaki Institute for Biomedical Innovation, could enable personalized glaucoma therapy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730149</guid>
      <pubDate>Wed, 08 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730149-smart-contact-lens-delivers-adaptative-glaucoma-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-anatomy-and-contact-lens.webp?t=1775678594" type="image/jpeg" medium="image" fileSize="480794">
        <media:title type="plain">Eye anatomy and contact lens</media:title>
      </media:content>
    </item>
    <item>
      <title>Biogen to use Alloy Therapeutics’ Anticlastic ASO platform</title>
      <description>
        <![CDATA[Alloy Therapeutics Inc. has entered into a collaboration and license agreement with Biogen Inc. for the use of Alloy’s Anticlastic ASO platform to accelerate the development of innovative oligonucleotide therapeutics.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730189</guid>
      <pubDate>Wed, 08 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730189-biogen-to-use-alloy-therapeutics-anticlastic-aso-platform</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Researcher-antisense-oligonucleotides.webp?t=1775662140" type="image/jpeg" medium="image" fileSize="579461">
        <media:title type="plain">AI generated image for researcher developing antisense oligonucleotides</media:title>
      </media:content>
    </item>
    <item>
      <title>Dectisomes show potent activity against high-priority fungal pathogens</title>
      <description>
        <![CDATA[In previous work, researchers from the University of Georgia developed liposomes loaded with antifungal drugs and coated with the carbohydrate recognition domains of mouse dectin-1 and/or dectin-2, called Dectisomes. The murine Dectisomes efficiently bound and killed pathogenic fungi in vitro and in mouse disease models. In a new study, the team aimed to explore how to potentially move Dectisomes into the clinic with human dectin orthologues.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730167</guid>
      <pubDate>Tue, 07 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730167-dectisomes-show-potent-activity-against-high-priority-fungal-pathogens</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Mucorales-mucormycosis-black-fungus.webp?t=1706630288" type="image/jpeg" medium="image" fileSize="196888">
        <media:title type="plain">Colony of Mucorales grown on petri dish with microscopic illustration</media:title>
      </media:content>
    </item>
  </channel>
</rss>
